

Research · Science  
 Forschung · Wissenschaft  
 Recherche · Science

<b>Publisher</b> <b>Herausgeber</b> <b>Editeur</b>	<b>Editor-in-chief</b> <b>Chefredaktor</b> <b>Rédacteur en chef</b>	<b>Editors</b> <b>Redaktoren</b> <b>Rédacteurs</b>	<b>Assistant Editor</b> <b>Redaktions-Assistent</b> <b>Rédacteur assistant</b>
Schweizerische Zahnärzte- Gesellschaft SSO Société Suisse d'Odonto-Stomatologie CH-3000 Bern 7	Prof. Adrian Lussi Klinik für Zahnerhaltung, Präventiv- und Kinderzahnmedizin Freiburgstrasse 7 3010 Bern	Andreas Filippi, Basel Susanne Scherrer, Genève Patrick R. Schmidlin, Zürich	Simon Flury, Bern Klaus Neuhaus, Bern Brigitte Zimmerli, Bern

Articles published in this section have been reviewed by members of the Editorial Review Board.

Jede im Teil «Forschung und Wissenschaft» des SDJ eingereichte Arbeit wird von zahnärztlichen Fachpersonen begutachtet. Diese genaue Begutachtung macht es möglich, dass die Publikationen einen hohen wissenschaftlichen Standard aufweisen.

Ich bedanke mich bei den unten aufgeführten Kolleginnen und Kollegen für ihre wertvolle Mitarbeit, die sie in den vergangenen zwei Jahren geleistet haben.

Adrian Lussi

M. Altenburger, Freiburg	A. Friedmann, Witten	H. T. Lübbers, Zürich	P. R. Schmidlin, Zürich
N. Arweiler, Marburg	K. W. Grätz, Zürich	H. -U. Luder, Männedorf	A. Sculean, Bern
T. Attin, Zürich	S. Hänni, Bern	R. Männchen, Winterthur	R. Seemann, Bern
U. Blunck, Berlin	E. Hellwig, Freiburg	G. Menghini, Zürich	U. Thüer, Meikirch
M. M. Bornstein, Bern	I. Hitz Lindenmüller, Basel	A. Mombelli, Genève	H. van Waes, Zürich
V. Chappuis, Bern	R. Jacobs, Leuven	K. Neuhaus, Bern	T. von Arx, Bern
D. Dagassan-Berndt, Basel	C. Katsaros, Bern	I. Nitschke, Zürich	C. Walter, Basel
S. Eick, Bern	N. Kellerhoff, Bern	C. Ramseier, Bern	T. Waltimo, Basel
T. Eliades, Zürich	S. Kiliaridis, Genf	S. Ruf, Giessen	R. Weiger, Basel
N. Enkling, Bern	K. Kislig, Bern	G. Salvi, Bern	M. Zehnder, Zürich
A. Filippi, Basel	J. T. Lambrecht, Basel	M. Schätzle, Luzern	B. Zimmerli, Bern
S. Flury, Bern	K. Lädach, Bern	S. Scherrer, Genève	N. U. Zitzmann, Basel

PATRICK R. SCHMIDLIN<sup>1,2</sup>  
HELEN ENGLISH<sup>4</sup>  
WARWICK DUNCAN<sup>2</sup>  
GEORGIOS N. BELIBASAKIS<sup>3</sup>  
THOMAS THURNHEER<sup>3</sup>

<sup>1</sup> Clinic of Preventive Dentistry, Periodontology and Cariology, Center of Dental Medicine, University of Zurich, Switzerland

<sup>2</sup> Sir John Walsh Research Institute, School of Dentistry, University of Otago, Dunedin, New Zealand

<sup>3</sup> Section of Oral Microbiology and Immunology, Institute of Oral Biology, Center of Dental Medicine, University of Zurich, Switzerland

<sup>4</sup> Nelson Periodontics, Private Specialist Periodontal Practice, Nelson, New Zealand

#### CORRESPONDENCE

Prof. Dr. med. dent.  
Patrick R. Schmidlin  
Clinic of Preventive Dentistry, Periodontology and Cariology, Center of Dental Medicine, University of Zurich  
Plattenstrasse 11  
CH-8032 Zürich  
Switzerland  
Tel. +41 44 634 32 84  
Fax +41 44 634 43 08  
E-mail: patrick.schmidlin@zsm.uzh.ch

SWISS DENTAL JOURNAL 124:  
922–927 (2014)  
Accepted for publication:  
22 October 2013

## Antibacterial potential of Manuka honey against three oral bacteria *in vitro*

#### KEYWORDS

honey, antimicrobial, periodontitis, caries

#### ABSTRACT

Honey is an ancient natural remedy for the treatment of infected wounds. It has regained attention in the medical profession, as it has recently been reported to have a broad-spectrum inhibitory effect against bacteria. Data concerning Manuka honey of New Zealand origin, which is claimed to provide additional non-peroxide antimicrobial activity (so-called standard NPA) against oral pathogens, is still scarce.

Therefore, this study aimed to screen for the antibacterial efficacy of different Manuka honey products against *S. mutans* (OMZ 918), *P. gingivalis* (OMZ 925) and *A. actinomycetemcomitans* (OMZ 299). Chlorhexidine and saline served as positive and negative controls, respectively, whereas a Swiss multifloral honey served as control honey without intrinsic non-peroxide activity.

Chlorhexidine showed the highest inhibiting potential against all specimens tested. Manuka honey below an NPA value of 15 showed the least bacterial growth-inhibiting potential, even less – although not significantly so – than multifloral Swiss honey. Manuka honey above an NPA value of 15 showed a significantly higher antibacterial effect compared to the other honeys tested. All Manuka honey preparations were more effective in inhibiting the growth of *P. gingivalis* and *A. actinomycetemcomitans*, rather than *S. mutans*.

In conclusion, the study showed an NPA dose-dependent antibacterial efficacy of Manuka honey. Further investigations of this natural product are now open for scrutiny.

## Introduction

Gingivitis and periodontitis are bacterial infections modified by systemic and environmental factors (PAGE & KORNMAN 1997). The main treatment target remains the effective reduction of the supra- and subgingival pathogenic flora, mainly by mechanical means. A variety of antibiotics and antiseptics have been introduced as adjunct to mechanical therapy (GREENSTEIN 2005). Whereas the use of systemic antibiotics is warranted in certain cases, it is associated with risks, notably the development of antibiotic resistance in various bacterial species (BIDAULT ET AL.

2007). However, administration of subgingival and topical antimicrobial agents as a quick and inexpensive means of supporting mechanical periodontal debridement is worth consideration (SLOTS 2002). Apart from well-investigated and established antiseptics frequently used in gingivitis/periodontitis prophylaxis and treatment protocols like chlorhexidine or iodine, natural products would be a desirable alternative (MOLAN 2001). Among them, natural products such as bee honey have a great potential to be used as adjuncts to mechanical periodontal treatment and infection control.

Honey is an ancient remedy for the experiential treatment of infected wounds and has recently been “rediscovered” by the medical profession. It has been reported to have a broad-spectrum inhibitory effect against bacteria and yeasts (ALLEN ET AL. 1991, WILLIX ET AL. 1992) and contains an enzyme that produces hydrogen peroxide when diluted (WHITE ET AL. 1963). The importance of the additional antibacterial activity of honey is demonstrated in several studies comparing the therapeutic effects of honey and sugar (POSTMES 1997, BOSE 1982, SOMERFIELD 1991, FRENCH ET AL. 2005). The hydrogen peroxide concentration produced in honey activated by dilution is around 1 mmol/l (MOLAN 1992), which is about 1,000 times less than in the 3% solution commonly used as an antiseptic (GUPTA 1973). Although the level of enzymatic hydrogen peroxide production in honey is very low, it is still effective as an antimicrobial agent and produces no harmful effects on tissue due to its excellent biocompatibility (MARTIN & PILEGGI 2004, OZAN ET AL. 2007). However, most honey loses its antibacterial activity after treatment with catalase which eliminates hydrogen peroxide activity.

But additional non-peroxide antibacterial factors have been identified. Manuka honey, in particular, demonstrates this type of activity. Manuka is the common name of *Leptospermum scoparium*, a tea tree from New Zealand (LUSBY ET AL. 2002). This non-peroxide antibacterial effect is caused by methylglyoxal, found in high doses in Manuka honey (ADAMS ET AL. 2008, MAVRIC ET AL. 2008). The level of non-peroxide activity in Manuka honey is referred to by a standard NPA (Non Peroxide Activity) value, also trademarked in New Zealand as UMF (“Unique Manuka Factor”). This number refers to the equivalent percentage of phenol antiseptic in water, i.e. NPA 15 (or UMF 15) equates to an antibacterial activity greater or equal to a 15% solution (%w/v) of phenol/water.

The antimicrobial potential of honey has been evaluated and a wide range of MIC values (minimum concentration of honey necessary for complete inhibition of bacterial growth) have been reported in studies comparing different honeys against single species of bacteria (FRENCH ET AL. 2005). However, although there is evidence of its antimicrobial efficacy on non-oral pathogens, data concerning the specific activity of Manuka honey against oral pathogens is scarce (ENGLISH ET AL. 2004). The aim of the present study was therefore to evaluate the antibacterial efficacy of different Manuka honey products against three well established putative oral pathogens *in vitro* using an agar diffusion method as well as determinations of the minimal inhibitory concentrations (MIC) and minimal bactericidal concentrations (MBC). We hypothesized that Manuka honey would exhibit superior antibacterial efficacy than other commonly consumed honey types, in a dose-dependent manner.

## Materials and methods

Semi-liquid honey formulations were tested on *Aggregatibacter actinomycetemcomitans* (OMZ 299), *Porphyromonas gingivalis* (OMZ 925) and *Streptococcus mutans* (OMZ 918). For the inoculum, the three strains were grown separately in growth medium containing fluid universal medium (FUM; GMÜR & GUGGENHEIM 1983), supplemented with 67 mmol/l Sørensen’s buffer, final pH 7.2) and 0.3% glucose. Towards the end of the exponential growth phase the optical density of the cell suspensions was measured at a wavelength of 550 nm and adjusted by dilution with FUM to an optical density of 1.0. Columbia Blood Agar (CBA) without addition of blood (Becton Dickinson Microbiology Systems, Sparks, MD, USA) was prepared according to the


manufacturer’s instructions. The agar was kept in a water bath at 50°C until further use. For each strain, Petri dishes were prepared by mixing 20 ml of agar with 1 ml of the corresponding inoculum. After hardening of the culture medium, wells measuring 5 mm in diameter were punched out. These cavities were then filled with the different materials. The following honey products were tested:

- a) Swiss multifloral honey (Apiary Halbheer, Rüti, Switzerland)
- b) Manuka honey NPA 5+ (Watson & Son, Masterton, New Zealand)
- c) Manuka honey NPA 15+ (Watson & Son, Masterton, New Zealand)
- d) Manuka honey Label “MGO 400+”, equivalent to NPA 20+ (Manuka Health New Zealand Ltd, Te Awamutu, New Zealand)
- e) Manuka honey NPA 25+ (Watson & Son, Masterton, New Zealand)
- f) MediHoney™ Medical Honey (Comvita® Derma Sciences Maidenhead, UK)
- g) MediHoney™ Gel Sheet (Comvita® Derma Sciences Maidenhead, UK)

All honey preparations were maintained at 35°C for 1 hour before use to make them more flowable and then the products were filled in the vial to completely fill the well (Fig. 1). Chlorhexidine (0.2%, Kantonsapotheke, Zürich, Switzerland) and sterile physiologic saline served as controls (filling the well corresponded to 40 µl). In the case of the gel sheet, a standardized punch sample 4 mm was taken and placed in the well, which was then filled with sterile saline (40 µl). After 48 hours of anaerobic incubation at 37°C, the zones of inhibition were measured using a caliper. The experiments were performed in triplicate.

In addition, MIC and MBC of the best performing honey in the agar diffusion test were determined with liquid cultures in 96-well flat-bottom polystyrene microtitre test plates (Milian, Wohlen, Switzerland) as described in details earlier (SHAPIRO ET AL. 1994). In short, Manuka NPA 25+ honey solutions were prepared using FUM at concentrations of 50, 20, 10, 4, 2, 1, and 0% w/v and were tested on the same three microorganisms as described above for the agar diffusion tests. For each bacterial strain one microtitre plate was used and for each dilution 6 wells were used. Five of the latter served to determine the MIC, whereas the 6<sup>th</sup> well was needed for MBC determinations. Plates with wells containing 180 µl of growth medium (100% growth controls) and 180 µl of honey solution were covered with plastic lids and pre-reduced for 45 minutes at 37°C in an anaerobic incubator (Microincubator MI22NK, Scholzen Microbiology Systems AG, Necker, Switzerland), then inoculated with 20 µl of a bacterial culture adjusted to an optical density at 550 nm ( $OD_{550}=0.5\pm 0.05$ ). After 48 hours of anaerobic incubation at 37°C (Microincubator MI22NK), each plate was covered with a plastic foil (Plate Sealers, Microtec, Embrach, Switzerland) and vigorously shaken for 10 seconds (model AM 69 micro-shaker, Dynatech, Kloten, Switzerland) and immediately scanned (492 nm) using an Epoch microplate spectrophotometer (BioTek, Luzern, Switzerland). The MIC was defined as the minimal honey concentration that precluded growth ( $OD_{492}<0.05$ ).

For MBC 25 µl of the corresponding honey concentrations used for MIC testing were withdrawn from the microtitre plate, stroked on Columbia Blood Agar plates (CBA) (Difco, Basing-



**Fig.1** Preparation of the agar plates: After hardening of the agar plate, wells were punched (A) and the agar was sucked (B). Finally the materials were carefully applied to fill the vial (C).

stoke, Hamps, UK) and incubated anaerobically for 48 hours at 37°C. Bacterial growth was visually analysed using a stereomicroscope (Stemi 2000, Carl Zeiss, Feldbach, Switzerland). The MBC was defined as the minimal concentration of the honey that reduced the colony-forming units/ml by 4 orders of magnitude relative to the 100% growth controls.

#### Data presentation and statistical analyses

The zones of inhibition (mm) were calculated according to the following formula:  $(D-5\text{ mm})/2$ , where D represents the greatest extent of the diameter including the well diameter. Therefore the diameter of the well was subtracted. The statistical analysis was performed using computer software (StatView® 4.02, Abacus Concepts, Berkeley, CA, USA). Results were presented in mean values and standard deviations. One-way ANOVA followed by Scheffé post-hoc testing was used to determine the

significant differences between groups. P values smaller than 5% were considered to be statistically significant.

#### Results

The results of the agar diffusion test are summarized in Table 1.

Chlorhexidine showed the highest inhibiting potential against all specimens tested. As expected, saline, which was used as a negative control, showed no antibacterial effect. Manuka honey below an NPA value of 15 showed the least bacterial growth-inhibiting potential, even less – although not significantly so – than multiflora Swiss honey, which also showed a considerable antibacterial effect. Manuka honey above an NPA value of 15+ showed a significantly higher antibacterial effect compared to the other honeys tested, with the exception of MediHoney, that showed a comparable antimicrobial effect as Manuka honey for *P. gingivalis*. However, there was no or little

**Tab.1** Zones of inhibition in mm (mean ± standard deviation) around the different preparations (identical superscript capitals represent values which do not differ statistically significantly from each other (ANOVA, Scheffé, read vertically) with regard to the bacterial strain tested)

	<i>S. mutans</i>	<i>P. gingivalis</i>	<i>A. actinomycetemcomitans</i>
Multiflora honey (CH)	1.2 ± 0.1 <sup>AB</sup>	3.1 ± 1.1 <sup>A</sup>	3.5 ± 0.5 <sup>AB</sup>
Manuka honey 5+	0.8 ± 0.5 <sup>AC</sup>	2.8 ± 0.6 <sup>A</sup>	3.9 ± 0.3 <sup>BC</sup>
Manuka honey 15+	3.1 ± 0.3 <sup>D</sup>	4.3 ± 0.1 <sup>B</sup>	4.9 ± 0.2 <sup>DE</sup>
Manuka honey 20+	3.2 ± 0.2 <sup>D</sup>	5.2 ± 0.3 <sup>B</sup>	4.7 ± 0.7 <sup>BCD</sup>
Manuka honey 25+	3.7 ± 0.6 <sup>D</sup>	5.6 ± 0.6 <sup>B</sup>	5.8 ± 0.1 <sup>F</sup>
MediHoney	2.0 ± 0.1 <sup>B</sup>	5.0 ± 0.3 <sup>B</sup>	5.3 ± 0.1 <sup>F</sup>
MediHoney, gel sheet	0.0 ± 0.0 <sup>C</sup>	2.0 ± 0.6 <sup>A</sup>	2.3 ± 0.4 <sup>A</sup>
Chlorhexidine 0.2%	10.3 ± 0.1 <sup>E</sup>	11.8 ± 0.4 <sup>C</sup>	9.7 ± 0.3 <sup>G</sup>
Saline	0.0 ± 0.0 <sup>C</sup>	0.0 ± 0.0 <sup>D</sup>	0.0 ± 0.0 <sup>H</sup>

**Tab.II** Average optical densities (OD<sub>492</sub>) after growth on different concentrations of Manuka honey 25+ (n=5).

Manuka honey dilution	Bacterial strains tested		
	<i>A. actinomycetemcomitans</i>	<i>P. gingivalis</i>	<i>S. mutans</i>
1:100	0.593	0.877	1.163
1:50	0.541	0.839	1.077
1:25	<b>0.010*</b>	0.790	0.952
1:10	0.010	<b>0.014</b>	0.687
1:5	0.005	0.019	<b>0.009</b>
1:2	0	0	0.006

\*Bold values indicate MICs

significant difference between the three Manuka honey samples with an NPA<sub>≥15+</sub>, indicating an optimal effect at this NPA value. It is also worth noting that all Manuka honey preparations were more effective in inhibiting the growth of *P. gingivalis* and *A. actinomycetemcomitans*, rather than *S. mutans*.

MIC and MBC of Manuka honey 25+ were determined, because this compound showed the best activity against all bacterial strains under investigation. Since – from a practical perspective – honey was dissolved in fluid, dilutions instead of concentrations are reported. The average optical densities (OD<sub>492</sub>) of the tested bacteria after growth on Manuka honey 25+ dilutions used for MIC determinations are listed in Table 2. The MIC for *A. actinomycetemcomitans*, *P. gingivalis*, and *S. mutans* accounted for 1:25, 1:10, and 1:5, respectively. The lowest dilution required to kill these bacteria was >1:2 for all three bacterial strains.

## Discussion

This study tested the growth inhibiting effect of different Manuka honey products against three well established oral pathogens *in vitro* using an agar diffusion method. The study showed antibacterial efficacy, which was dose-dependent, but an NPA level greater than 15+ showed comparable properties, which were more pronounced than the control honey and – surprisingly – than the MediHoney.

In general, an NPA (non-peroxide activity) rating of 10 is considered the minimum for therapeutic efficacy. Our study supports this in finding that NPA 5+ showed no superior effect. Therefore, ‘ordinary’ Manuka honey has only hydrogen peroxide antibacterial properties, which are common to most types of honey, as corroborated in this study. In contrast, Manuka honey with an NPA of 10+ and greater has both the natural hydrogen peroxide antibacterial property and its own natural non-peroxide antibacterial properties, giving it increased antibacterial potency.

In addition, when discussing the therapeutic effects of honey, a difference between ‘normal’ honey (meant for alimentary consumption) and so-called ‘medical’ honey (approved for therapeutic use) has to be made. Most of the ‘normal’ honey products undergo heat treatment before landing on supermarket shelves, which destroys the enzyme responsible for the hydrogen peroxide production; whereas the ‘medical’ honey is sterilized by gamma irradiation, which ensures persisting activity of hydrogen peroxidase (LUSBY ET AL. 2002). In addition, antimicrobial activity of different honeys varies considerably, even

if gained from the same floral source. However, using this agar diffusion test, the differences at high concentrations were not considerable. The percentages of the various components depend on the plant of origin and its geographic location, the season it was collected, its treatment since harvest and its age (LUSBY ET AL. 2002). In this study, we used the agar diffusion method as well as MIC/MBC determinations. Different screening methods to determine antibacterial activity are available: E.g. variants of the agar diffusion method (well and disc), bioautographic methods (direct and indirect) and microdilution assay. A comparative study has found that the well variant of the diffusion method was more sensitive than the disc variant (VALGAS ET AL. 2007). Bioautographic and diffusion techniques, however, were found to have similar sensitivity. But the latter technique provided even more suitable conditions for the microbial growth. Therefore, the agar diffusion method may still offer good option to screen the antibacterial effect of natural products (SCHMIDLIN ET AL. 2003). Since the antimicrobial effects of the Manuka honey upon single oral pathogens are confirmed by this study, the next step would be to validate the efficacy of these honey preparations on an *in vitro* multi-species biofilm model.

Despite the positive results of this study, the therapeutic usage of Manuka honey in periodontal pockets remains questionable and still needs critical evaluation. Although Manuka honey displayed an antibacterial potential, it was still weaker than the control compound chlorhexidine. Therefore, the clinical usefulness can be questioned. However, the ongoing search and evaluation of natural products is still warranted (National policy on traditional medicine and regulation of herbal medicines: Report of a WHO global survey. World Health Organization. ISBN 92 4 159323 7) and Manuka one option to be considered as a natural antiseptic alternative, especially for patients seeking complementary agents and alternatives for synthetic chemicals.

Preparation of the dressing is sticky, and handling in clinical situations (e.g. application into the depth of the periodontal pocket) will be challenging. Saliva and sulcus fluid may lead to quick liquefaction of the honey, and cause insufficient resting time in the periodontal pocket for the development of antibacterial effects. Honey allergy, even though very rare, can lead to various clinical symptoms including anaphylaxis (KARAKAYA & FUAT KALYONCU 1999). Another factor to consider is root caries development. Especially when treating difficult-to-clean furcation areas, honey can pose a considerable caries risk that should not be underestimated. However, as shown in the pres-

ent study, Manuka honey even displayed an antimicrobial activity against the cariogenic bacteria *S. mutans*. Our findings are corroborated by past research demonstrating activity of Manuka honey against organisms in dental plaque that cause decay, along with inhibition of acid formation (BADET & QUERO 2011). In addition, it must be emphasized that the application of the honey would be indicated only after careful debridement, i.e. removal of plaque, which also reduces the potential risk of caries development, and that no long-time applications are possible, which also minimizes the risk of pain and hypersensitivity on exposed root surfaces following contact with highly osmolar honey.

All these clinical aspects should be taken into consideration and critically assessed before proceeding further to clinical applications. Therefore, tests using an *in vitro* oral biofilm model are planned, for further validation of the antimicrobial activities of the Manuka honey and the demineralizing effect of this natural antibacterial compound. These studies will also focus on the incorporation of other natural antibacterial products (TAKARADA ET AL. 2004), e.g. propolis.

## Acknowledgements

The authors would like to thank the valuable help from André Meier, Ruth Graf, Beatrice Sener, and Professor Peter Molan.

## Résumé

Le miel est un ancien remède naturel pour le traitement des plaies infectées. En tant que produit naturel, il représente un intérêt pour la médecine dentaire. L'effet antibactérien du miel s'explique essentiellement par plusieurs mécanismes. De par sa forme de sucre hautement concentré, le miel agit par osmose et donc avec effet antibactérien. D'autre part, du peroxyde d'hydrogène est formé en solution aqueuse par l'action d'enzymes intrinsèques. D'autres mécanismes d'action antibactériens, sans association avec le peroxyde, ont été décrits avec le méthylglyoxal, qui représente une activité métabolique connue sous l'abréviation de NPA (non peroxide activity): plus la valeur du NPA est élevée, plus actif est le mécanisme d'action antibactérien. Ce NPA se trouve augmenté dans le miel de manuka de Nouvelle-Zélande. Toutefois, les résultats concernant l'activité antimicrobienne ici sont encore rares, surtout en ce qui concerne les agents pathogènes parodontaux. Le but de la présente étude était d'évaluer le potentiel antibactérien de différents produits de miel contre *Streptococcus mutans* (OMZ 918), *Porphyromonas gingivalis* (OMZ 925) et *Aggregatibacter actinomycetemcomitans* (OMZ 299) avec un test simple de dépistage de laboratoire. La chlorhexidine et du sérum physiologique ont été utilisés respectivement comme contrôle positif et négatif, tandis qu'un miel de fleurs suisse a servi de contrôle sans aucune activité spécifique de NPA. Toutes les substances ont été analysées dans des plaques d'Agar pour déterminer le développement de foyers d'inhibition de croissance bactérienne. Des trous ont été percés dans les plaques d'Agar contenant les souches bactériennes et remplis avec la préparation de miel spécifique en quantité standardisée. Au terme d'une période d'incubation appropriée, les foyers d'inhibition ont été mesurés.

La chlorhexidine a montré le potentiel inhibiteur le plus élevé contre toutes les bactéries testées. Le miel de manuka d'une valeur NPA en dessous de 15 a montré la plus faible inhibition de la croissance bactérienne, légèrement en dessous de l'inhibition mesurée du miel de fleurs suisse – bien que sans différence sta-

tistique significative. Les miels de manuka ayant une valeur NPA supérieure à 15 ont par contre montré des effets antibactériens plus élevés que tous les autres types de miel testés en ce qui concerne l'inhibition de *P. gingivalis* et *A. actinomycetemcomitans*. Par contre pour *S. mutans*, l'effet inhibiteur était plus faible.

Ainsi, cette étude a montré une activité antibactérienne dose-dépendante du miel de manuka. Toutefois, il reste à démontrer dans quelle mesure l'efficacité contre la prolifération bactérienne de germes individuels observée dans un test de laboratoire est aussi valable dans un environnement de biofilms complexes ou même dans des conditions *in vivo*.

## Zusammenfassung

Honig ist ein altes Naturheilmittel im Rahmen der Behandlung infizierter Wunden. Als Naturprodukt ist es wieder in den Fokus der Zahnmedizin gerückt. Die antibakterielle Wirksamkeit von Honig kann grundsätzlich durch mehrere Mechanismen erklärt werden: Einerseits wirkt Honig bereits als konzentrierte Zuckerform osmotisch und damit antibakteriell, zum andern wird durch intrinsische Enzyme Wasserstoffperoxid in wässriger Lösung gebildet. Es wurden aber auch sogenannte nicht-Peroxid-assoziierte Wirkmechanismen respektive Aktivitäten beschrieben, welche zum Beispiel durch Methylglyoxal in Erscheinung treten. Diese Aktivität wird mit NPA abgekürzt (je höher der Wert, umso aktiver ist der Honig). Letztere findet sich vermehrt in Manukahonig aus Neuseeland. Daten bezüglich der antimikrobiellen Wirksamkeit sind hierbei jedoch noch spärlich, vor allem im Hinblick auf parodontale Krankheitserreger. Daher war es das Ziel der vorliegenden Studie, das antibakterielle Potenzial verschiedener Honigprodukte gegen *Streptococcus mutans* (OMZ 918), *Porphyromonas gingivalis* (OMZ 925) und *Aggregatibacter actinomycetemcomitans* (OMZ 299) in einem einfachen Laborscreeningverfahren zu evaluieren. Chlorhexidin und Kochsalzlösung dienten als Positiv- und Negativkontrollen, wohingegen ein herkömmlicher Schweizer Blütenhonig als Kontrolle ohne NPA diente. Alle Substanzen wurden in Agar bezüglich Hemmhofentwicklung analysiert. Zu diesem Zweck wurden Löcher in die mit Bakterien versetzten Agarplatten gestanzt und die Präparate darin in standardisierter Menge eingebracht. Nach entsprechender Inkubationszeit wurden die Hemmhöfe vermessen.

Chlorhexidin zeigte das höchste Hemmpotential gegen alle getesteten Bakterien. Manukahonig unter einem Wert von 15 NPA zeigte die geringste Bakterienwachstumshemmung. Diese lag noch unterhalb der Bakterieninhibition des Schweizer Blütenhonigs – wenngleich nicht statistisch signifikant. Manukahonig-Sorten über einem Wert von 15 NPA zeigten im Vergleich zu den anderen getesteten Honigsorten hingegen eine deutlich höhere antibakterielle Hemmwirkung gegen *P. gingivalis* und *A. actinomycetemcomitans*. Bezüglich *S. mutans* war die Wirksamkeit geringer.

Somit zeigte die Studie eine dosisabhängige antibakterielle Wirksamkeit von Manukahonig. Inwieweit nun diese im Labor festgestellte Wirksamkeit gegen ein Bakterienwachstum von Einzelkeimen im einfachen Agartestverfahren auch bei komplexen Biofilmen oder *in vivo* wirksam ist, muss allerdings noch gezeigt werden.

## References

- ADAMS C J, BOULT C H, DEADMAN B J, FARR J M, GRAINGER M N, MANLEY-HARRIS M, SNOW M J:** Isolation by HPLC and characterisation of the bioactive fraction of New Zealand manuka (*Leptospermum scoparium*) honey. *Carbohydr Res* 343: 651–659 (2008)
- ALLEN K L, MOLAN P C, REID G M:** A survey of the antibacterial activity of some New Zealand honeys. *J Pharm Pharmacol* 43: 817–822 (1991)
- BADET C, QUERO F:** The in vitro effect of manuka honeys on growth and adherence of oral bacteria. *Anaerobe* 17: 19–22 (2011)
- BEAN A:** Anti-inflammatory properties of honey. University of Waikato PhD thesis, 2012.
- BIDAULT P, CHANDAD F, GRENIER D:** Risk of bacterial resistance associated with systemic antibiotic therapy in periodontology. *J Can Dent Assoc* 73: 721–725 (2007)
- BOSE B:** Honey or sugar in treatment of infected wounds? *Lancet* 1: 963 (1982)
- ENGLISH H K, PACK A R, MOLAN P C:** The effects of manuka honey on plaque and gingivitis: a pilot study. *J Int Acad Periodontol* 6: 63–67 (2004)
- FRENCH V M, COOPER R A, MOLAN P C:** The antibacterial activity of honey against coagulase-negative staphylococci. *J Antimicrob Chemother* 56: 228–231 (2005)
- GMÜR R, GUGGENHEIM B:** Antigenic heterogeneity of *Bacteroides intermedius* as recognized by monoclonal antibodies. *Infect Immun* 42: 459–470 (1983)
- GREENSTEIN G:** Position paper: The role of supra- and subgingival irrigation in the treatment of periodontal diseases. *J Periodontol* 76: 2015–2027 (2005)
- GUPTA B L:** Microdetermination techniques for hydrogen peroxide in irradiated solutions. *Microchem J* 18: 363–374 (1973)
- KARAKAYA G, FUAT KALYONCU A:** Honey allergy in adult allergy practice. *Allergol Immunopathol (Madr)* 27: 271–272 (1999)
- LUSBY P E, COOMBS A, WILKINSON J M:** Honey: a potent agent for wound healing? *J Wound Ostomy Continence Nurs* 29: 295–300 (2002)
- MARTIN M P, PILEGGI R:** A quantitative analysis of Propolis: a promising new storage media following avulsion. *Dent Traumatol* 20: 85–89 (2004)
- MAVRIC E, WITTMANN S, BARTH G, HENLE T:** Identification and quantification of methylglyoxal as the dominant antibacterial constituent of Manuka (*Leptospermum scoparium*) honeys from New Zealand. *Mol Nutr Food Res* 52: 483–489 (2008)
- MOLAN P C:** The antibacterial activity of honey. 1. The nature of the antibacterial activity. *Bee World* 73: 5–28 (1992)
- MOLAN P C:** The potential of honey to promote oral wellness. *Gen Dent* 49: 584–589 (2001)
- OZAN F, POLAT Z A, ER K, OZAN U, DEGER O:** Effect of propolis on survival of periodontal ligament cells: new storage media for avulsed teeth. *J Endod* 33: 570–573 (2007)
- PAGE R C, KORNMAN K S:** The pathogenesis of human periodontitis: an introduction. *Periodontol* 2000 14: 9–11 (1997)
- POSTMES T J, BOSCH MMC, DUTRIEUX R, VAN BAARE J:** Speeding up the healing of burns with honey. An experimental study with histological assessment of wound biopsies. In: Mizrahi A, Lensky Y, editors. *Bee Products: Properties, Applications and Apitherapy*. Plenum Press, New York, pp 27–37 (1997)
- SHAPIRO S, MEIER A, GUGGENHEIM B:** The antimicrobial activity of essential oils and essential oil components towards oral bacteria. *Oral Microbiol Immunol* 9: 202 (1994)
- SCHMIDLIN O A, ZEHNDER M, SCHMIDLIN P R:** Effectiveness of dentine bonding agents against cariogenic bacteria in vitro: a comparison of two methods. *Oral Microbiol Immunol* 18: 140–143 (2003)
- SLOTS J:** Selection of antimicrobial agents in periodontal therapy. *J Periodontol* 37: 389–398 (2002)
- SOMERFIELD S D:** Honey and healing. *J R Soc Med* 84: 179 (1991)
- TAKARADA K, KIMIZUKA R, TAKAHASHI N, HONMA K, OKUDA K, KATO T:** A comparison of the antibacterial efficacies of essential oils against oral pathogens. *Oral Microbiol Immunol* 19: 61–64 (2004)
- VALGAS C, MACHADO DE SOUZA S, SMANIA E F A, SMANIA JR A:** Screening methods to determine antibacterial activity of natural products. *Braz J Microbiol* 38: 369–380 (2007)
- WHITE J W J, SUBERS M H, SCHEPARTZ A I:** The identification of inhibine, the antibacterial factor in honey, as hydrogen peroxide and its origin in a honey glucose-oxidase system. *Biochim Biophys Acta* 73: 57–70 (1963)
- WILLIX D J, MOLAN P C, HARFOOT C G:** A comparison of the sensitivity of wound-infecting species of bacteria to the antibacterial activity of manuka honey and other honey. *J Appl Bacteriol* 73: 388–394 (1992)